Early achievement of measurable residual disease negativity in the treatment of multiple myeloma as predictor of outcome.

MLA

Baumelou, Marion, et al. “Early Achievement of Measurable Residual Disease Negativity in the Treatment of Multiple Myeloma as Predictor of Outcome.” British Journal of Haematology, vol. 197, no. 6, June 2022, pp. e82–85. EBSCOhost, https://doi.org/10.1111/bjh.18103.

APA

Baumelou, M., Payssot, A., Row, C., Racine, J., Lafon, I., Bastie, J., Chevreux, S., Chrétien, M., Maynadié, M., Caillot, D., & Guy, J. (2022). Early achievement of measurable residual disease negativity in the treatment of multiple myeloma as predictor of outcome. British Journal of Haematology, 197(6), e82–e85. https://doi.org/10.1111/bjh.18103

Chicago

Baumelou, Marion, Alexandre Payssot, Celine Row, Jessica Racine, Ingrid Lafon, Jean‐Noél Bastie, Steeve Chevreux, et al. 2022. “Early Achievement of Measurable Residual Disease Negativity in the Treatment of Multiple Myeloma as Predictor of Outcome.” British Journal of Haematology 197 (6): e82–85. doi:10.1111/bjh.18103.